Transcatheter arterial chemoembolization for liver metastases in patients with adrenocortical carcinoma

Journal of Vascular and Interventional Radiology

Volumn 21, Issue 10, 2010, Pages 1527-1532

  Cazejust, Julien ^a   De Baère, Thierry ^a   Auperin, Anne ^a   Deschamps, Frédéric ^a   Hechelhammer, Lukas ^a   Abdel Rehim, Mohamed ^a   Schlumberger, Martin ^a   Leboulleux, Sophie ^a   Baudin, Eric ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IODINATED POPPYSEED OIL;

ABDOMINAL PAIN; ADOLESCENT; ADRENAL CORTEX CARCINOMA; ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; CANCER GROWTH; CANCER INVASION; CANCER PATIENT; CANCER SIZE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; FEMALE; FEVER; HUMAN; LIVER METASTASIS; MALE; NAUSEA AND VOMITING; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR NECROSIS;

ADOLESCENT; ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ADULT; AGED; CATHETERIZATION, PERIPHERAL; CHEMOEMBOLIZATION, THERAPEUTIC; FEMALE; HEMOSTATICS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77957823233     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvir.2010.05.020     Document Type: Article

References (33)

1. C. Gicquel, E. Baudin, Y. Lebouc, and M. Schlumberger Adrenocortical carcinoma Ann Oncol 8 1997 423 427
2. B. Allolio, and M. Fassnacht Adrenocortical carcinoma: clinical update J Clin Endocrinol Metab 91 2006 2027 2037
3. L.M. Weiss Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors Am J Surg Pathol 8 1984 163 169
4. L.M. Weiss, L.J. Medeiros, and A.L. Vickery Jr Pathologic features of prognostic significance in adrenocortical carcinoma Am J Surg Pathol 13 1989 202 206
5. C. Gicquel, X. Bertagna, and V. Gaston Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors Cancer Res 61 2001 67622767
6. G. Abiven, J. Coste, and L. Groussin Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients J Clin Endocrinol Metab 91 2006 2650 2655
7. G. Assie, G. Antoni, and F. Tissier Prognostic parameters of metastatic adrenocortical carcinoma J Clin Endocrinol Metab 92 2007 148 154
8. A. Berruti, M. Terzolo, and P. Sperone Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial Endocr Relat Cancer 12 2005 657 666
9. H. Ahlman, S. Jansson, and B. Wangberg Adrenocortical carcinomadiagnostic and therapeutical implications Eur J Surg 159 1993 149 158
10. D.E. Schteingart, G.M. Doherty, and P.G. Gauger Management of patients with adrenal cancer: recommendations of an international consensus conference Endocr Relat Cancer 12 2005 667 680
11. M.D. Wooten, and D.K. King Adrenal cortical carcinoma Epidemiology and treatment with mitotane and a review of the literature Cancer 72 1993 3145 3155
12. E. Baudin, G. Pellegriti, and M. Bonnay Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p′DDD) levels on the treatment of patients with adrenocortical carcinoma Cancer 92 2001 1385 1392
13. H.R. Haak, J. Hermans, and C.J. van de Velde Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients Br J Cancer 69 1994 947 951
14. K.A. Olaussen, A. Dunant, and P. Fouret DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy N Engl J Med 355 2006 983 991
15. E. Baudin, C. Docao, and C. Gicquel Use of a topoisomerase I inhibitor (irinotecan, CPT-11) in metastatic adrenocortical carcinoma Ann Oncol 13 2002 1806 1809
16. L.S. Kirschner Emerging treatment strategies for adrenocortical carcinoma: a new hope J Clin Endocrinol Metab 91 2006 14 21
17. M. Quinkler, S. Hahner, and S. Wortmann Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine J Clin Endocrinol Metab 93 2008 2057 2062
18. P. Haluska, F. Worden, and D. Olmos Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma Cancer Chemother Pharmacol 65 2009 765 773
19. Lindsay CR, Chan E, Evans TR, et al. Phase I dose escalation study of continuous oral dosing of OSI-906, an insulin like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor, in patients with advanced solid tumors. Presented at the 45th Scientific Assembly of the American Society of Clinical Oncology; May 29 to June 2, 2009; Orlando, FL.
20. C.V. Lindsay, C.T. Downs, and M. Brown Physiological variation in amethyst sunbirds (Chalcomitra amethystina) over an altitudinal gradient in winter J Exp Biol 212 2009 483 493
21. M.F. Brennan Adrenocortical carcinoma CA Cancer J Clin 37 1987 348 365
22. J.M. Llovet, and J. Bruix Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival Hepatology 37 2003 429 442
23. B.K. Eriksson, E.G. Larsson, B.M. Skogseid, A.M. Lofberg, L.E. Lorelius, and K.E. Oberg Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors Cancer 83 1998 2293 2301
24. S. Gupta, M.M. Johnson, and R. Murthy Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival Cancer 104 2005 1590 1602
25. A. Roche, B.V. Girish, and T. de Baere Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors Eur Radiol 13 2003 136 140
26. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
27. A. Trotti, A.D. Colevas, and A. Setser CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment Semin Radiat Oncol 13 2003 176 181
28. A. Roche, B.V. Girish, and T. de Baere Prognostic factors for chemoembolization in liver metastasis from endocrine tumors Hepatogastroenterology 51 2004 1751 1756
29. C.M. Lo, H. Ngan, and W.K. Tso Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma Hepatology 35 2002 1164 1171
30. M. Varela, M.I. Real, and M. Burrel Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics J Hepatol 46 2007 474 481
31. Coenegrachts K, de Baère T, Abdel Rehim M, Lafont C, Dromain C, Hakime A. Transarterial chemoembolization (TACE) of neuroendocrine hepatic metastases using drug eluting beads. Presented at the 91st Scientific Assembly of the Radiological Society of North America; November 27 to December 2, 2005; Chicago, IL.
32. K. Hong, A. Khwaja, E. Liapi, M.S. Torbenson, C.S. Georgiades, and J.F. Geschwind New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer Clin Cancer Res 12 2006 2563 2567
33. R.A. Decker, and M.E. Kuehner Adrenocortical carcinoma Am Surg 57 1991 502 513